KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Other Non-Current Liabilities (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $21.6 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 48.03% to $21.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.6 million through Dec 2025, up 48.03% year-over-year, with the annual reading at $21.6 million for FY2025, 48.03% up from the prior year.
  • Other Non-Current Liabilities hit $21.6 million in Q4 2025 for Vir Biotechnology, up from $13.3 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $33.2 million in Q3 2024 to a low of $2.5 million in Q4 2021.
  • Historically, Other Non-Current Liabilities has averaged $15.8 million across 5 years, with a median of $14.0 million in 2024.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 72.84% in 2021 and later soared 638.52% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $2.5 million in 2021, then soared by 337.6% to $11.1 million in 2022, then skyrocketed by 42.01% to $15.8 million in 2023, then fell by 7.65% to $14.6 million in 2024, then surged by 48.03% to $21.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for VIR at $21.6 million in Q4 2025, $13.3 million in Q3 2025, and $13.0 million in Q2 2025.